POLIVY in combination with bendamustine and rituximab product is the first and only regimen approved by the FDA based on a randomized trial that studied patients with R/R DLBCL 1

R/R=relapsed/refractory; DLBCL=diffuse large B-cell lymphoma.

Patient Resource Center

The Genentech Patient Resource Center

Offering services and information to providers and their patients receiving POLIVY
Call 1 (877) GENENTECH (436-3683)
Monday-Friday, 6 AM-5 PM PST